Drugs

Coalition letter to HHS and CMS Regarding the CMS Registry for Alzheimer's Treatments

It is essential that all data collected by any of the registries are made publicly available for research...

Coalition Letter to FDA Commissioner Califf Regarding FDA Advisory Committee Meetings

The Coalition expressed our strong concerns when the Food and Drug Administration (FDA) Center Directors...

Coalition comment to CMS on on CT Quality Measures Included in the Proposed Rule for the Hospital Inpatient Quality Reporting (IQR) Program

We support this CT quality measure because it establishes a floor and a ceiling to provide an optimal...

Meeting of Patient, Consumer, and Public Health Coalition with Commissioner Califf and Key FDA Officials

The Patient, Consumer, and Public Health Coalition, scheduled a hybrid meeting with FDA Commissioner...

Coalition Letter to Congress on CMS Limited Coverage for Newly Approved Alzheimer’s Drugs

February 27, 2023: The Coalition urges Congress to support the decision by the Centers for Medicare and...

Coalition letter to CMS on Lecanemab approval and maintaining their coverage decision

We applaud your National Coverage Determination limited coverage of this class of drugs solely to patients...

Joint Letter from from Cancer Groups and Patient-Centered Nonprofits about VALID Act in Omnibus

We are writing to express our strong support for your bipartisan support for the VALID Act earlier this...

Coalition Letter to MAP workgroups on CT quality measures

We are writing to enthusiastically support the CT quality measures developed by researchers at the University...

Coalition Letter To Senate HELP And Energy And Commerce Committee On User Fee Reauthorization Legislation

It is critically important that House and Senate committees work together to consolidate differences...

Coalition Letter to Senate HELP and Energy and Commerce Committee on User fee reauthorization legislation

We write to urge you to expeditiously consolidate the two pieces of legislation to reauthorize the Food...

February 10, 2022

Public Comments to CMS on Aduhelm for the treatment of Alzheimer’s disease

Patient, Consumer, and Public Health Coalition provides public comments on Aduhelm and similar medical products for the treatment of Alzheimer’s disease